Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nantes University Hospital
Injection of a bispecific anti-CEA x anti-HSG antibody TF2 (120 nmoles) and 30 hours later IMP-288 peptide labeled with gallium-68 (3 to 6 nmoles/150 MBq). A TEP imaging acquisition is plannified 60 min after the 68-Ga injection.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Existence of one or more metastases of of colorectal cancer (CRC) expressing the CEA , potentially accessible by surgical or thermo resection at the moment of the diagnosis or at relapse.
OR
Isolated and progressive elevation of plasma CEA during the monitoring of CRC with high metastatic risk
More than 18 years
Negative pregnancy test for women of childbearing age. Women of childbearing age should take effective continuous contraception for 3 months.
At least 4 weeks after the last treatment and after recovery of potential toxicity
Karnofsky more than 70 or ECOG 0-1
Life expectancy of at least 6 months
CEA positive immunohistochemistry or plasma CEA supperior or equal to the normal level
Creatinin less or equal 200 micromol/L
Signed informed consent
geographical proximity
You may not be if
Pregnancy or breastfeeding
Serious illness or comorbidity assessed risk
History of other cancer within 5 years, with the exception of skin carcinomas other than melanomas or in-situ carcinoma of the cervix
Anti-antibody presence in patients who have already received antibody
Hypersensitivity to antibodies or proteins
Intellectual inability to sign the informed consent
Insulin-dependent diabetic patient or non-insulin dependent
Clareo Health | ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer
